Good morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and invigorating, because the usual routine of deadline, meetings, and whatnot has forcefully returned. You knew this would happen, yes? To cope, as you can guess, we are quaffing cups of stimulation. As always, you are invited to join us. Remember, no prescription is required. Meanwhile, here are some tidbits for you to enjoy. Hope you have a smashing day and do keep in touch …
Amgen and UCB disclosed their experimental osteoporosis drug, which is awaiting US regulatory approval, yielded a higher rate of serious heart problems that were not seen in earlier studies. Although the drug met the primary and key secondary goals of a late-stage study, Amgen does not expect approval this year. Evercore ISI analyst Umer Raffat wrote this is “very surprising,” noting Wall Street expected $800 million in peak annual sales.
About the Author Reprints
